News Daxor Corporation NYSE

Stocks

DXR

US2394671034

Closed End Funds

Market Closed - NYSE 16:30:00 2026-09-04 EDT			5-day change	1st Jan Change
10.27 ^USD	-2.66%		-1.72%	-30.37%

08-31	Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-30	Daxor Launches Blood Testing Lab in Eastern Kansis	MT

All News

Mentions Relevance

09-01	Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter	AQ
08-31	Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-30	Daxor Launches Blood Testing Lab in Eastern Kansis	MT
07-30	Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas	CI
07-29	Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas	AQ
07-07	Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas	AQ
06-02	Daxor Says Received US Patent for Remote Blood Volume Monitor Technology	MT
06-02	Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor	AQ
04-28	Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis	AQ
04-26	5,061,267 Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 27-APR-2026.	CI
04-08	Daxor Corporation Expands Customer Footprint With New BVA Program At High-Volume Ohio Cardiology Center	CI
04-08	Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center	AQ
03-26	Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026	AQ
03-26	Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data	CI
03-17	Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26	CI
03-17	Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions	AQ
03-10	Daxor Corporation Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026, Mar-10-2026 through Mar-11-2026
03-10	Daxor Corporation Showcases New Portable Blood Volume Analyzer	CI
03-10	Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress	AQ
03-09	Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026	AQ
03-04	Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share	AQ
03-03	Daxor Corporation CEO and President Michael Feldschuh provides corporate update in letter to shareholders	RE
03-03	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders	AQ
03-03	Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share	AQ
03-02	Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI